



325 N. Fourth Street
Libertyville, IL 60048

M.D./alert[®]

PRSR STD
US Postage
PAID
/alert Marketing



GLAXOSMITHKLINE SAFETY ADVISORY

February 9, 2015

Dear Healthcare Professional:

Title: TIMENTIN® (ticarcillin disodium and clavulanate potassium) for Injection – Cessation of Manufacture for the US

Therapeutic Indication

TIMENTIN® is a combination of a β -lactam antibacterial and a β -lactamase inhibitor indicated for the treatment of the following infections due to designated susceptible bacteria:

- Septicemia
- Lower respiratory infections
- Bone and joint infections
- Skin and skin structure infections
- Urinary tract infections
- Gynecologic infections
- Intra-abdominal infections

We wish to alert you that GlaxoSmithKline has ceased manufacturing TIMENTIN® for the US.

Key Messages

- GlaxoSmithKline would like to advise you that after careful consideration, we have discontinued manufacturing all TIMENTIN® formulations and strengths
- No new manufacturing will take place, and there is no further supply available.
- This decision is not related to any safety or efficacy concern, but reflects available alternative treatments and declining global demand

Action Being Taken by GlaxoSmithKline

- GlaxoSmithKline has informed the US Food and Drug Administration of our decision to cease manufacturing TIMENTIN® for the US

Action required by Health Care Providers

- You should share this information with relevant health care personnel under your supervision and/or in your institution
- You should consider alternative treatments for your patients.

Further Information

This decision has been posted on the US Food and Drug Administration Drug Shortage website:

<http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>

Please see accompanying full Prescribing Information for TIMENTIN.

Contact for Further Information or Questions

GlaxoSmithKline regrets any inconvenience this decision may have on your practice.

For all questions, please contact David J. Chang, at David.J.Chang@GSK.com.

Sincerely,



David J. Chang, MD, MPH

VP and Head, Immuno-Inflammation, Infectious Diseases, and Rare Diseases

US Medical Affairs

GlaxoSmithKline

Enclosure: TIMENTIN® Full Prescribing Information

Please see accompanying full Prescribing Information for TIMENTIN.

